Advanced searches left 3/3

CAR-T Cells Tumors - Europe PMC

Summarized by Plex Scholar
Last Updated: 05 May 2022

* If you want to update the article please login/register

Olfactory Receptor OR2H1 is an effective target for CAR T cells in human epithelial tumors.

Despite the fact that chimeric antigen receptor expressing T cells has demonstrated success in hematologic tumors, their use in solid tumors has been largely unsuccessful so far. Quantification of OR2H1 expression in solid epithelial tumors restricted to the testis showed widespread OR2H1 expression in 17 normal tissues, 82 ovarian cancers of various histologies, 8 non-small cell lung cancers, and 17 breast cancers. Importantly, OR2H1 protein signal was found in 60 human lung cancers, 40 ovarian carcinomas, and 73 cholangiocarcinomas with similar to mRNA expression and without OR2H1 staining in 58 normal tissues. Therefore, T cells transplanted against OR2H1-expressing tumor cells, presumably with an acceptable toxicity profile, and with an acceptable toxicity profile.

Source link: https://europepmc.org/article/MED/35499393


Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice.

We have established a way by which OVs and CAR T cells in immunocompetent mouse models can potentiate CAR T cell survival against solid tumor models of melanoma and glioma. Dual-specific CAR T cells were boosted by in vitro preloading with oncolytic vesicular virus (Reovirus) or reovirus, allowing for further expansion and reactivation of T cells by homologous boosting, which allowed for a further in vivo expansion and reactivation of T cells. Human CD19 CAR T cells could also be expanded in vitro with TCR reactivity against viral or virally encoded antigens, and was associated with increased CAR-directed cytokine production. Our findings show that combining OV and CAR T cell therapy enhances CAR T cell proliferation and safety in mice, as well as showing that stimulation of the native TCR can be exploited to improve mouse TCR function and efficacy.

Source link: https://europepmc.org/article/MED/35417192


Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors.

Adoptive cell therapy has been highly effective in treating blood cancers, but standard approaches to ACT are not as effective in treating solid tumors that are observed clinically. When compared to standard intravenous administration methods, novel delivery systems for solid tumor removal or in immune-privileged tissues have demonstrated promise for treating solid tumors, but the few reported approaches use biomaterials that are difficult to manufacture and have limited utility following tumor removal or in immune-privileged tissues.

Source link: https://europepmc.org/article/MED/35394838


Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors.

For the successful use of chimeric antigen receptor T cell therapy in solid tumors, major hurdles must be overcome. Infiltration, growth, and persistence of CAR T cells can be affected by additional immune systems in the solid tumor microenvironment. Redirecting CAR T cells toward the tumor vasculature might be a viable option, as molecular targets of tumor endothelial cells can be directly recruited from within the blood.

Source link: https://europepmc.org/article/MED/35202772

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions